Post-Marketing Safety Assessment of CAR T-Cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase

被引：0
|
作者：
Alrasheed, Meshael [1 ]
Alhawas, Solaiman [1 ]
Alorf, Nora S. [2 ]
Al-Fadel, Nouf [3 ]
Alharbi, Fawaz [3 ]
机构：
[1] Saudi Food & Drug Author SFDA, Riyadh, Saudi Arabia
[2] Saudi Food & Drug Author, Riyadh, Saudi Arabia
[3] Saudi Food & Drug Author, Drug Sect, Drug Safety & Risk Management Dept, Execut Directorate Pharmacovigilance, Riyadh, Saudi Arabia
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1185
引用
收藏
页码：533 / 534
页数：2
相关论文
共 50 条
  • [1] Individual Case Safety Reports and VigiBase: The Vital Importance of Quality
    Salistedt, L.
    Johonsson, J.
    Wilmar, H.
    Lindquist, M.
    DRUG SAFETY, 2012, 35 (10) : 922 - 923
  • [2] Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Christiane Michel
    Emil Scosyrev
    Michael Petrin
    Robert Schmouder
    Clinical Drug Investigation, 2017, 37 : 415 - 422
  • [3] Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel, Christiane
    Scosyrev, Emil
    Petrin, Michael
    Schmouder, Robert
    CLINICAL DRUG INVESTIGATION, 2017, 37 (05) : 415 - 422
  • [4] Ibrutinib: A post-marketing safety analysis.
    Elias, Rawad
    Pudusseri, Anita
    Akinboro, Oladimeji
    White, Paul S.
    Sarosiek, Shayna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab
    Li, Huqun
    Wang, Chongshu
    Guo, Cuilian
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2025, 13 (03):
  • [6] Post-Marketing Safety of ALK inhibitors: An Analysis of EudraVigilance reports Between 2012 and 2022
    Lipovec, Nanca Cebron
    Knez, Lea
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 306 - 307
  • [7] Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase(R) the WHO Global Database of Individual Case Safety Reports
    Crosnier, Alexandre
    Abbara, Chadi
    Cellier, Morgane
    Lagarce, Laurence
    Babin, Marina
    Bourneau-Martin, Delphine
    Briet, Marie
    CANCERS, 2021, 13 (23)
  • [8] TNF ANTAGONIST DRUG SAFETY ASSESSMENT BY PHARMACOVIGILANCE SIGNALING AND POST-MARKETING ADVERSE EVENT REPORTS
    Cavaco, M.
    Araujo, F.
    Eurico Fonseca, J.
    Goncalves, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 784 - 785
  • [9] Safety monitoring of ophthalmic biologics: analysis of pre and post-marketing safety data
    Penedones, Ana
    Batel-Marques, Francisco
    PHARMACOTHERAPY, 2014, 34 (06): : E86 - E86
  • [10] Addressing safety issues and providing safety assessment to regulatory authorities in the post-marketing period
    Czarnecki, A.
    DRUG SAFETY, 2007, 30 (10) : 940 - 940
12345